Your browser doesn't support javascript.
loading
The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi, Qi; Shen, Lu-Yan; Dong, Bin; Fu, Hao; Kang, Xiao-Zheng; Yang, Yong-Bo; Dai, Liang; Yan, Wan-Pu; Xiong, Hong-Chao; Liang, Zhen; Chen, Ke-Neng.
Afiliação
  • Shi Q; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Shen LY; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Dong B; Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Fu H; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Kang XZ; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Yang YB; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Dai L; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Yan WP; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Xiong HC; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Liang Z; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Chen KN; Department of Thoracic Surgery I, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China. Electronic address: chenkeneng@bjmu.edu.cn.
Cancer Lett ; 432: 56-68, 2018 09 28.
Article em En | MEDLINE | ID: mdl-29890208
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirazinas / Neoplasias Esofágicas / Carcinoma de Células Escamosas / Cisplatino / Resistencia a Medicamentos Antineoplásicos / Proteínas Mutadas de Ataxia Telangiectasia / Isoxazóis Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirazinas / Neoplasias Esofágicas / Carcinoma de Células Escamosas / Cisplatino / Resistencia a Medicamentos Antineoplásicos / Proteínas Mutadas de Ataxia Telangiectasia / Isoxazóis Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2018 Tipo de documento: Article